UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, but growth may accelerate after 2026. Read more here.

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.

It operates through the following segments: Diagnostics and Pharmaceuticals ... Read More on RHHVF: Roche NewsMORE Related Stocks Indices Commodities ...

With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient access to personalised treatment. Basel, 31 January ...

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics ...

The Diagnostics division’s sales rose 4% year ... However, pipeline setbacks weigh on the stock. Roche also expects loss of exclusivity for key drugs to impact adversely sales to the tune ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...